Zürich (ots) - Gestern Sonntag, dem 20. August, ging Allianz Cinema Zürich mit dem Hollywood-Blockbuster ...
FibroScan® New Generation Extends Access to Non-invasive Liver Diagnosis
Paris (ots/PRNewswire) - Echosens (http://www.echosens.com/en/) extends its product range with the launch of a new FibroScan® product, the reference liver diagnosis equipment, at EASL 2016 in Barcelona: FibroScan® 530 Compact.
The FibroScan® 530 Compact is designed to increase access to the exclusive FibroScan® VCTE(TM) (Vibration Controlled Transient Elastography) and CAP(TM) (Controlled Attenuation Parameter) technologies to monitor fibrosis, cirrhosis and steatosis. As a mobile, easy-to-handle and battery-operated device, FibroScan® (http://www.fibroscan.com/en/products) 530 Compact extends availability for patients without access to centers with FibroScan® capabilities.
FibroScan® is supported by over 1,300 peer-reviewed publications and is the reference for the AASLD, EASL-ALEH, and WHO guidelines liver disease.
FibroScan® products, including the new FibroScan® models, are designed with several quality control systems to support consistency of scan results, irrespective of operator or location. This delivers comparability of results across locations, FibroScan® models, and operators. This consistency provides better information to support patient management, as well as a tool for tracking of results, publishing data and clinical research.
Echosens is taking the opportunity to provide ELPA (http://www.elpa-info.org/) (European Liver Patients Association) with its first FibroScan® 530 Compact at its booth (2200H) during EASL (http://www.easl.eu/) 2016 (the International Liver Congress(TM)) on 14th April at 3:30pm. This mobile device is intended to be used for non-profit liver screening campaigns throughout Europe.
Echosens is an innovative high-technology company based in France. Since its inception in 2001, Echosens has been recognized as the world's leading provider of non-invasive diagnostic devices for chronic liver diseases. The company's innovative, non-invasive technologies are recognized for cost effectively diagnosing and monitoring chronic liver diseases with precision, standardization and repeatability over time and users. The Group owns three products lines: FibroScan®, FibroMeter®, FibroView® which are covered by several families of patents owned by Echosens.
Facebook (https://www.facebook.com/fibroscan.echosens/) | Twitter (https://twitter.com/myliverexpert) | LinkedIn (https://www.linkedin.com/company/echosens) | YouTube (https://www.youtube.com/user/EchosensTV)
For any further information, please contact:
Echosens Communication Dpt. email@example.com Tel: +33-1-44-82-78-50